On Friday, Piper Sandler adjusted its outlook on Regeneron (NASDAQ:) Prescription drugs (NASDAQ: REGN) shares, rising the worth goal to $1,166 from the earlier $1,000 whereas sustaining an Obese score on the inventory. The agency’s resolution is available in mild of recent survey outcomes that bolster a constructive view of the corporate’s portfolio, notably its Eylea product.
The surveys, performed in April and Could, centered on Age-related Macular Degeneration (AMD (NASDAQ:)) and Diabetic Macular Edema (DME), every involving roughly 100 individuals.
The findings are seen as affirming the analyst’s optimistic stance on Regeneron’s general enterprise, particularly the projected market share for Eylea HD, which helps greater than consensus estimates.
Regardless of the encouraging survey outcomes, Piper Sandler made slight changes to its quarterly estimates for the 2mg dosage of Eylea, elevating the forecast for the second quarter of 2024 however lowering expectations for the third and fourth quarters of the identical 12 months, in addition to for the complete 12 months of 2025. These tweaks, nevertheless, don’t considerably alter the agency’s long-term estimates, which stay considerably above the consensus by way of 2025.
The revised worth goal additionally displays a mix of different mannequin changes and the next valuation a number of. This a number of growth aligns with developments noticed throughout the broader pharmaceutical sector. The agency’s analyst maintains a assured stance on Regeneron, encouraging buyers to proceed shopping for shares.
In different current information, Regeneron Prescription drugs has seen vital developments. UBS has elevated its worth goal for the corporate, reflecting optimism about Regeneron’s income prospects, notably noting the higher-than-expected Sanofi (NASDAQ:) collaboration income. Regardless of this, UBS revised its 2025 EPS prediction for Regeneron barely downwards, bearing in mind cost-related revisions.
Regeneron’s strategic deal with genetic medication, emphasised by senior management, has been bolstered by collaborative efforts and a mergers and acquisitions technique. Numerous analyst companies, together with BMO Capital Markets, Argus Analysis, and RBC Capital Markets, have adjusted their worth targets for Regeneron, reflecting confidence within the firm’s progress trajectory.
Moreover, the FDA has accepted Regeneron’s Kevzara for kids with lively polyarticular juvenile idiopathic arthritis and expanded approval for Praluent. The corporate can also be anticipating FDA and European Fee approvals for linvoseltamab and Dupixent for numerous therapies. These current developments point out a promising outlook for Regeneron Prescription drugs.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
